UK|Use of Cannabis-based medicinal products: NICE guidelines

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis-based medicinal products NICE guideline [NG144]Published date: November 2019 Guidance Tools and resources Evidence History Overview Recommendations Recommendations for research Rationale and impact Context Finding more information and committee details Share Download Guidance Next  Recommendations 1.1 Intractable nausea and vomiting 1.2 Chronic pain 1.3 Spasticity 1.4 Severe treatment-resistant epilepsy 1.5 Prescribing Terms used in this guideline People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding. 1.1 Intractable nausea and vomiting 1.1.1Consider nabilone as an add-on treatment for adults (18 years and over) with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics. 1.1.2When considering nabilone for adults with chemotherapy-induced nausea and vomiting, take into account potential adverse drug interactions, for example, with central nervous system depressants and other centrally active drugs. To find out why the committee made the recommendations on intractable nausea and vomiting and how they might affect practice, see rationale and impact . 1.2 Chronic pain 1.2.1Do not offer…

Excerpt only …
Link to original : Use of Cannabis-based medicinal products: NICE guidelines
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.